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Radiofrequency Ablation of Liver Cancer:
Early Evaluation of Therapeutic Response
with Contrast-Enhanced Ultrasonography
The early assessment of the therapeutic response after percutaneous radiofre-
quency (RF) ablation is important, in order to correctly decide whether further
treatment is necessary. The residual unablated tumor is usually depicted on con-
trast-enhanced multiphase helical computed tomography (CT) as a focal enhanc-
ing structure during the arterial and portal venous phases. Contrast-enhanced
color Doppler and power Doppler ultrasonography (US) have also been used to
detect residual tumors. Contrast-enhanced gray-scale US, using a harmonic
technology which has recently been introduced, allows for the detection of resid-
ual tumors after ablation, without any of the blooming or motion artifacts usually
seen on contrast-enhanced color or power Doppler US. Based on our experience
and reports in the literature, we consider that contrast-enhanced gray-scale har-
monic US constitutes a reliable alternative to contrast-enhanced multiphase CT
for the early evaluation of the therapeutic response to RF ablation for liver can-
cer. This technique was also useful in targeting any residual unablated tumors
encountered during additional ablation.
he recent development of various image-guided tumor ablation
techniques has provided a new therapeutic modality, whose objective is
the complete eradication of hepatic tumors (1). Amongst these different
techniques, percutaneous radiofrequency (RF) ablation is an outstanding therapy that
induces localized coagulation of the tumor by creating resistive ionic heating through
the electrode (2 6). The early evaluation of the therapeutic response after RF
ablation is critical, in order for a correct decision to be made as to whether further
treatment (i.e. additional ablation) is necessary. The residual unablated tumor is
usually depicted on contrast-enhanced multiphase helical CT as a focal enhancing
structure during the arterial and portal venous phases (3 5, 7). Contrast-enhanced
ultrasonography (US) has also been used by many investigators to detect residual
tumors (8 11). Since percutaneous RF ablation is usually performed under US
guidance, US evaluation of the therapeutic response seems to be preferable (2 5).
Several intravenous contrast agents including SH U 508A (Levovist; Schering AG,
Berlin, Germany) have been used, because neither gray-scale US, nonenhanced color
Doppler US nor power Doppler US can provide satisfactory information on the
completeness of RF ablation, owing to their low sensitivity to small vessels with slow
flow (8, 9). Some prior reports suggested that contrast-enhanced color Doppler and
power Doppler US provide improved depiction of residual unablated tumors in the
ablation zone (8, 9, 12). Recently, contrast-enhanced gray-scale US using a harmonic
technology has been introduced for the evaluation of the therapeutic response to RF
ablation (10, 11, 13, 14). This new technique allows for the detection of residual
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Tviable tumors after ablation, without any of the blooming
or motion artifacts seen on contrast-enhanced color or
power Doppler US. According to our experience of
treating 1,300 liver cancers with percutaneous RF ablation,
contrast-enhanced US is as accurate as contrast-enhanced
multiphase helical CT for the early depiction of residual
unablated tumors. This technique was also useful in target-
ing residual unablated tumors during the process of
additional ablation. In this article, we describe the different
methods of performing the contrast-enhanced US examina-
tion, which is used for the early evaluation of the therapeu-
tic response. We also present our results, and discuss the
strengths and weaknesses of these different techniques.
POSTABLATION IMAGING STRATEGY
From April 1999 to October 2003, 1,300 liver cancers
were treated with US-guided percutaneous RF ablation in
our institution. Of these, 1,140 were hepatocellular
carcinomas (HCCs). To perform the percutaneous RF
ablation, various kinds of RF devices manufactured by
three different companies (Radiofrequency Interstitial
Thermal Ablation Medical System, Mountain View, Cal;
RadioTherapeutics Corporation, Mountain View, Cal; and
Radionics Corporation; Burlington, Mass) were used (3-5).
Details concerning the preparation of the patients and the
ablation techniques used have previously been reported (7,
9, 12, 14).
Immediately after the percutaneous RF ablation, all of
the patients were evaluated by means of a gray-scale US
examination, in order to detect whether any acute compli-
cations had occurred. For the early evaluation of the
therapeutic response, we performed either contrast-
enhanced US or CT or both. The postprocedural contrast-
enhanced CT examinations were performed with a helical
scanner (HiSpeed; GE Medical Systems, Milwaukee, Wis)
immediately (within 2 hours) after the RF ablation. Images
were obtained before, and 30, 70 and 180 seconds after
the initiation of the intravenous contrast material injection,
representing the nonenhanced, hepatic arterial, portal
venous and equilibrium phases, respectively. The following
morning, contrast-enhanced US examinations were
performed using a real-time US scanner (HDI 5000,
Advanced Technology Laboratories, Bothell, Wash;
LOGIQ 9 or LOGIQ 700 Expert Series, GE Medical
Systems, Milwaukee, Wis; or Sequoia, Siemens Medical
Solutions, Mountain View, Cal), following the injection of
a microbubble contrast agent. The microbubble contrast
agent that we used, SH U 508A, is a suspension of
galactose in sterile distilled water. In this contrast agent,
the tiny microbubbles (2-8  m) are stabilized in the
microparticle suspension. This agent was prepared by
vigorous shaking with 11 mL of water for 10 seconds. A
suspension of microbubbles and galactose microparticles
was created by disaggregation of the granules. After
standing for 2 minutes, 12.5 mL of a 300 mg/mL suspen-
sion was administered through an antecubital vein.
All patients underwent follow-up four-phase helical CT-
both nonenhanced and contrast-enhanced three-phase-
scans 1 month after RF ablation as a baseline study for the
evaluation of the therapeutic efficacy. We used either
contrast-enhanced US or CT or both for the early assess-
ment of complications and/or macroscopic residual
unablated tumors, since it was generally difficult to depict
microscopic residual tumors, due to the presence of either
reactive hyperemia or procedure-related arterioportal
shunts. The final decision on the early therapeutic efficacy
was made on the basis of 1-month follow-up CT findings,
since it is known that the reactive hyperemia is usually
resolved by this time (7). When found, residual unablated
tumors were usually treated with additional RF ablation. If
the condition of residual tumor was not adequate for
additional RF ablation, due to its poor conspicuity on US
or the presence of multiple new lesions, transcatheter
arterial chemoembolization (TACE) was performed. If
there was any evidence of the technical success of the local
treatment and no new HCC appeared in the other liver site
on the 1-month follow-up CT, subsequent contrast-
enhanced three-phase helical CT was repeated at 3-month
intervals as our follow-up strategy.
On the follow-up CT, we considered the tumor to be
completely ablated when there was no enhancing portion
within the ablation zone during either the hepatic arterial
or portal venous phase. Similarly, we regarded the tumor
as being completely ablated if there was neither vascularity
nor enhancing focus within the ablation zone on contrast-
enhanced US. A residual unablated tumor was defined as
an irregular peripheral-enhancing focus in the ablation
zone on either the contrast-enhanced US or early follow-
up CT, immediately or 1 month after RF ablation (7, 15).
Local tumor progression was considered as the presence of
growing enhancing tumors at the margin of the ablation
zone on later follow-up CT, when there had been no
previous evidence of a residual unablated tumor on the
contrast-enhanced US and early follow-up CT (15). As
described above, contrast-enhanced US has been used as
the key modality in the imaging strategy used to assess the
therapeutic efficacy following RF ablation in our institution
(Fig. 1).
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Power Doppler US
During the first one year period (between April 1999
and March 2000), most patients treated with percutaneous
RF ablation in our institution were evaluated with contrast-
enhanced power Doppler US after RF ablation. These
power Doppler US examinations were performed before
and after the injection of a microbubble contrast agent, and
the power Doppler US parameters were optimized. The
color gain was dynamically adjusted to detect slow flows
and to avoid noise. The pulse repetition frequency was
maintained at 700 Hz. We started to scan with power
Doppler US 20 seconds after initiation of the contrast
agent injection, which was performed at a rate of 3
mL/min with an infusion pump (IPX4; IVAC Medical
Systems, Hampshire, U.K.). We scanned intermittently to
avoid early bubble destruction. With this technique, the
enhancement effect lasted for more than 10 minutes. Focal
areas with flow signals in the ablated lesions were consid-
ered as viable tumor portions (9). In our previous report
involving the treatment of 73 hepatocellular carcinomas
(HCCs) (12), contrast-enhanced power Doppler US
showed no focal peripheral flow signals in 65 (89%)
ablation zones (Fig. 2). In the remaining eight (11%)
ablation zones, residual tumors were found on both the
immediate follow-up CT and contrast-enhanced power
Doppler US. The areas of the residual tumors on the
power Doppler US were well correlated with the enhanc-
ing portions on CT (Fig. 3). Hence, 100% diagnostic
agreement was achieved between the contrast-enhanced
power Doppler US and immediate follow-up CT. Of the 65
ablation zones without residual unablated tumors,
however, 10 (15%) had local tumor progression on follow-
up CT.
Pulse Inversion Harmonic Imaging (PIHI)
PIHI is one of the early-developed gray-scale harmonic
techniques (HDI 5000, Advanced Technology
Laboratories, Bothell, Wash). The transducer sends two
pulses into the tissue in rapid succession (one with a 180
phase change), and receives the sum of the echoes back
from the two inverted pulses. Consequently, the signals
from the harmonic component are boosted, and those from
the fundamental component are suppressed (16, 17).
Because microbubble agents produce nonlinear backscat-
ter, they respond differently to phase inverted pulses and
do not reflect identical inverted waveforms. According to
some previous reports (10, 16, 17), PIHI is superior to
conventional Doppler US or second harmonic US in the
depiction of tumor vascularity. Meloni et al. (10) pointed
out that contrast-enhanced PIHI has increased the sensitiv-
ity of detecting residual tumors after RF ablation by up to
83%. We also used this technique for a short period of
time (Fig. 4). Pulse inversion harmonic imaging (mechani-
cal index, MI, 1.1 1.3) was performed at 4- to 6-sec
intervals from 20 sec until 90 sec after initiation of the
contrast agent injection, using a single-frame acquisition
mode, rather than continuous imaging. The residual
unablated tumors were seen as focal enhancing structures
in the periphery of the ablation zone.
Coded Harmonic Angio (CHA)
CHA is the other contrast-specific gray-scale harmonic
US technique based on digitally encoding US technology
(LOGIQ 9 or LOGIQ 700 Expert Series, GE Medical
Systems, Milwaukee, Wis). This technique encodes the
unwanted fundamental frequency component when
transmitting pulses and then, through a decoding process
when receiving the signals, removes the pre-tagged
fundamental echoes without any loss or degradation of
overlapping harmonic signals (18 20). This leaves only
the desired wideband harmonic return signals, and allows
for superior contrast and spatial resolution over conven-
tional harmonic imaging techniques. CHA uses the B-flow
technique, as well as digitally coded harmonic imaging.
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Fig. 1. Imaging strategy used to assess the therapeutic efficacy
after radiofrequency ablation of liver cancer in our institution.The B-flow technique, which is optimized for the direct
visualization of blood cells on gray-scale images, uses
codes to enhance weak blood echoes and equalize the non-
moving tissue signal (19) Thus, the B-flow technique is free
of Doppler-related artifacts. By combining the benefits of
these two techniques, CHA allows the harmonic signals
resulting from tissue to be separated from those arising
from contrast agents, and boosts the harmonic return from
the contrast agents, while suppressing not only the
fundamental, but also the harmonic signals from the
background tissue (18 20). Hence, CHA is specifically
sensitive to signals from the contrast agent, without
Choi et al.
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Fig. 2. A 49-year-old-man with hepatocellular carcinoma before and after
successful radiofrequency ablation.
A. Contrast-enhanced CT obtained during the arterial phase before
radiofrequency ablation shows a 2.0-cm hepatocellular carcinoma (arrows)
with contrast enhancement in liver segment 8.
B. Nonenhanced power Doppler US before radiofrequency ablation shows
a few flow signals (arrowheads) in part of the hypoechoic tumor (arrows).
C. Contrast-enhanced power Doppler US shows multiple flow signals
(arrowheads) within the tumor.
D. Contrast-enhanced CT obtained 20 minutes after radiofrequency ablation
shows an ablation zone (arrows) of low attenuation, which represents the
technical success of radiofrequency ablation. Note that the ablation zone is
larger than the index tumor (i.e. the initially identified tumor prior to ablation).
E. Nonenhanced power Doppler US performed 18 hours after radiofre-
quency ablation shows the hypoechoic ablation zone without flow signal.
F. Contrast-enhanced power Doppler US again shows the ablation zone
(arrows) without flow signal.
G. On contrast-enhanced CT obtained 50 months after radiofrequency
ablation, the ablation zone is no longer seen. The patient is still alive without
recurrence.
Gproducing any contrast-related artifacts. This high sensitiv-
ity to the contrast agent creates a sufficiently stimulated
acoustic emission effect at only medium MI (0.6 0.8).
Furthermore, such a condition, which is less destructive
toward the microbubbles, provides a period of continuous
scanning with excellent depiction of the mobile microbub-
bles in the intratumoral microvasculature.
In interval-delay scanning, the imaging process is
interrupted for at least 10 seconds. This allows the entire
vascular volume, in which the microvessels are included, to
become filled with the contrast agent. When scanning
begins after a short intermission, the accumulated
microbubbles are destroyed, leading to the release of high-
intensity, nonlinear echoes that are optimally detected
using harmonic imaging. Stimulated acoustic emission does
not rely on the movement of microbubbles and can be
observed equally well with stationary microbubbles. Thus,
this harmonic interval-delay method allows the detection
of blood in the capillary bed, where the flow velocity is too
low to be detected with conventional Doppler US flow
techniques. In this way, gray-scale harmonic imaging can
be used to detect echoes from contrast agents, when it is
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Fig. 3. A 53-year-old-man with hepatocellular carcinoma before and after radiofrequency ablation.
A. Contrast-enhanced CT obtained during the arterial phase before radiofrequency ablation shows a 3.0-cm hepato-
cellular carcinoma (arrows) with contrast enhancement in segment 5.
B. Contrast-enhanced power Doppler US before radiofrequency ablation shows multiple flow signals (arrowheads)
within the index tumor (arrows).
C. Contrast-enhanced CT after radiofrequency ablation shows that most of the ablation zone is of low attenuation, but
a nodular enhancing focus (arrowheads) is noted in the posterior side of the ablation zone. This represents the
residual unablated tumor portion.
D. Contrast-enhanced power Doppler US shows peripheral flow signals (arrowheads) within the ablation zone
(arrows), which represent the residual tumor vessels. The residual unablated tumor was treated with additional
radiofrequency ablation.
CD
ABpresent in very low concentrations and distributed in
microscopic vessels.
Before the injection of the contrast agent, a preliminary
sweep was performed during suspended respiration in the
optimal plane for the visualization of the lesion. This data
was stored as a baseline cine loop. The machine settings,
such as the focal zone and time-gain compensation, were
optimized. Following this preliminary sweep, we obtained
serial contrast-enhanced CHA images from 15 to 90
seconds after the initiation of the bolus contrast injection.
We evaluated the vascularity within the ablation zones
with a continuous scan starting between 15 30 seconds
after initiation of the contrast injection, and lasting for 3 5
seconds. To evaluate the perfusion of the ablation zones,
we also obtained intermittent stimulated acoustic emission
imaging with a rapid sweeping technique every 10
seconds, from the end of the continuous scan to 90 seconds
after initiation of the contrast injection. We used intermit-
tent interval-delay scanning with 10-second intervals, in
order to avoid bubble destruction and to maximize the
stimulated acoustic emission. We froze the display in the
interval between each scanning time, and then unfroze it
for a very short period of time, during each scanning
period. Thus, we obtained five or six intermittent
stimulated acoustic emission imaging pieces during the
perfusion scanning. Focal areas with irregular peripheral
enhancement within the ablation zones were considered to
be residual tumor portions (9, 14). In our recent report
Choi et al.
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Fig. 4. A 58-year-old-woman with hepatocellular carcinoma before and after radiofrequency ablation.
A. Contrast-enhanced CT obtained during the arterial phase before radiofrequency ablation shows a 2.0-cm hepatocellular carcinoma
(arrows) with contrast enhancement in liver segment 8.
B. Before radiofrequency ablation, contrast-enhanced pulse inversion harmonic imaging obtained at 30 sec-delay shows most portions
of the tumor with contrast enhancement (arrows).
C. Contrast-enhanced CT obtained during the arterial phase 30 minutes after radiofrequency ablation shows oval-shaped ablation zone
(arrows) of low attenuation, which represents the technical success of radiofrequency ablation.
D, E. After radiofrequency ablation, contrast-enhanced pulse inversion harmonic imaging obtained at 20 and 80 sec-delay shows no
vascularity within the ablation zone (arrows).
F. Contrast-enhanced CT obtained 7 months after radiofrequency ablation, however, shows a small nodular enhancing focus (arrow) at
the peripheral margin of the ablation zone, which represents local tumor progression.
DE F
AB Cinvolving 81 HCCs (14), ten (12%) showed irregular
peripheral enhancement at the margin of the ablation zone
on contrast-enhanced CHA (Fig. 5). All of them were
found to have the enhancing portion at the same location
as that on the corresponding original image of the index
tumor, during the hepatic arterial or portal venous phases
on 1-month follow-up CT (Fig. 5). Contrast-enhanced
CHA showed no evidence of enhancing foci, suggesting
technical success in the remaining 71 (88%) of the 81
HCCs (Fig. 6). Among the 71 ablated HCCs without
residual unablated tumors, either on CT or contrast-
enhanced CHA, seven (10%) had follow-up CT findings of
local tumor progression in the ablation zones.
Agent Detection Imaging (ADI)
ADI (Sequoia, Siemens Medical Solutions, Mountain
View, Cal) is a multipulse technology that provides very
high-resolution images, and uses the property of bubble
emission to show regions where a contrast agent has
localized (21). ADI appears to be more useful for detecting
microbubble contrast in tumors than other harmonic
imaging techniques. Because ADI uses two pulses with the
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Fig. 5. A 57-year-old man with hepatocellular carcinoma before and after radiofrequency ablation.
A. Ferumoxides-enhanced T1-weighted fast multiplanar spoiled gradient-recalled echo image shows a 4.0-cm hepatocellular carcinoma
(arrows) with high signal intensity in liver segment 3.
B. After radiofrequency ablation, contrast-enhanced coded harmonic angio obtained at 30 sec-delay shows that most of the ablation
zone is avascular without enhancement, but a nodular enhancing focus (arrowheads) is seen at the inner aspect of the ablation zone.
The nodular enhancing portion represents the residual unablated tumor.
C. Contrast-enhanced CT obtained 1 month after radiofrequency ablation shows that most of the ablation zone is of low attenuation, but
a nodular enhancing portion (arrowheads) is seen at the posterior aspect of the ablation zone, which is identical to the location on US.
D. Contrast-enhanced CT obtained 1 month after additional radiofrequency ablation shows a low attenuating ablation zone with the
absence of contrast enhancement that represents technical success of radiofrequency ablation.
CD
ABsame polarity and subtracts the signals from the two
pulses, only those signals from the fundamental contrast
agent and harmonic contrast agent remain. As such, ADI
may be referred to as contrast-only imaging (21).
Moreover, ADI allows us to review either the functional
contrast-enhanced images, the anatomic tissue images, or
both at the same time, all from the same scan. Accordingly,
this capability of providing a segmented display on
contrast-enhanced ADI is very useful for depicting the
exact relationship between the index tumor (on the
Choi et al.
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Fig. 6. A 57-year-old-woman with hepatocellular carcinoma before and after
successful radiofrequency ablation.
A. Contrast-enhanced CT scan obtained during the arterial phase before
radiofrequency ablation shows a 1.5-cm hepatocellular carcinoma (arrows)
with contrast enhancement in liver segment 8.
B. Contrast-enhanced coded harmonic angio before radiofrequency
ablation shows most portions of the tumor with contrast enhancement
(arrows).
C. After radiofrequency ablation, contrast-enhanced coded harmonic angio
obtained at 30 sec-delay shows no vascularity within the ablation zone
(arrows).
D. Acoustic emission imaging with a rapid sweeping technique at 80 sec-
delay shows that all of the ablation zone is avascular without peripheral
enhancement (arrows).
E. Contrast-enhanced CT obtained 1 month after radiofrequency ablation
shows a round ablation zone (arrows) of low attenuation, with the absence
of contrast enhancement attesting to the technical success of the ablation.
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Fig. 7. A 72-year-old-man with hepatocellular carcinoma before and after successful radiofrequency ablation.
A. Contrast-enhanced CT scan obtained during the arterial phase before radiofrequency ablation shows a 2.8-cm hepatocellular
carcinoma (arrows) with contrast enhancement in liver segment 2. 
B. Contrast-enhanced agent detection imaging obtained at 18 sec-delay shows no vascularity within the ablation zone (arrows). 
C, D. Acoustic emission imaging with a rapid sweeping technique at 40 and 60 sec-delay shows that all of the ablation zone is avascular
without peripheral enhancement. The index tumor (arrowheads) with a satisfactory cancer-free ablative margin of the ablation zone is
noted.
E. Contrast-enhanced power Doppler US again shows the ablation zone without flow signal. Some artifacts are also seen.
F. Contrast-enhanced CT obtained 1 month after radiofrequency ablation shows a round ablation zone (arrows) of low attenuation with
the absence of contrast enhancement attesting to the technical success of the ablation.
EF
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ABanatomic tissue image) and the enhanced residual tumor
portion (on the image displaying tissue and contrast). ADI
is less focus dependent compared with CHA. However, the
relatively low frame rate of ADI might be a limitation.
The acoustic power of ADI was set at the default
(maximal) setting (MI, 1.9). The line density and frame rate
were set to a low level (9 Hz) with no frame averaging.
Scanning was performed with a 4-1-MHz or 6 2 MHz
convex array transducer. We obtained serial contrast-
enhanced ADI images from 15 to 90 seconds after initia-
tion of the bolus contrast injection. We evaluated the
vascularity within the ablation zones using a continuous
scan with a duration of 5 8 seconds, between 15 and 30
seconds after initiation of the contrast injection. To
evaluate the perfusion of the ablation zones, we also
obtained stimulated acoustic emission images with interval
delay scanning and a rapid sweeping technique during the
rest of the time. Each interval delay scanning was
interrupted for at least 10 seconds.
In our unpublished data concerning 52 HCCs, neither
contrast-enhanced ADI the following morning nor 1-month
follow-up CT showed evidence of enhancing foci within
the 49 (94%) ablation zones (Fig. 7). In the remaining
three (6%) ablation zones, irregular peripheral-enhancing
foci were found on contrast-enhanced ADI (Fig. 8). All of
these were found to have the enhancing portion at the
Choi et al.
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Fig. 8. A 44-year-old-man with hepato-
cellular carcinoma before and after
radiofrequency ablation. 
A. Contrast-enhanced CT scan before
radiofrequency ablation shows a 2.5-cm
hepatocellular carcinoma (arrows) with
contrast enhancement in liver segment 7.
B. In the morning following radiofre-
quency ablation, contrast-enhanced
agent detection imaging obtained at a 20
sec-delay shows some flow signals
(arrowheads) within the ablation zone.
C. Acoustic emission imaging with a
rapid sweeping technique at 80 sec-
delay shows that most of the ablation
zone is avascular without enhancement,
but an irregular peripheral enhancing
focus (arrowheads) representing the
residual tumor is seen.
D. Contrast-enhanced CT obtained 1
month after radiofrequency ablation
shows a small enhancing focus
(arrowhead) at the superior margin of the
ablation zone. Note the presence of
another small enhancing area represent-
ing an iatrogenic arterioportal shunt
(arrow) due to the ablation procedure.
AB
CDsame location as that of the corresponding lesions observed
during the hepatic arterial or portal venous phases on the
1-month follow-up CT (Fig. 8). Among the 49 ablated
HCCs without residual unablated tumors, either on CT or
contrast-enhanced ADI, two (4%) had follow-up CT
findings of local tumor progression in the ablation zones. A
more recent report (13) also suggested that contrast-
enhanced ADI was useful and as effective as CT for
evaluating the therapeutic response to RF ablation and
TACE in patients with malignant hepatic tumors (Fig. 9).
DISCUSSION
After RF ablation of liver cancer, it is very difficult to
detect residual unablated tumors using conventional color
Doppler or power Doppler US, because the internal blood
flows of the patients are slow and the signals are weak. As
previously described, contrast-enhanced US can improve
the detection of residual tumors in the ablation zone.
During and immediately after RF ablation, hypere-
chogenicity in the ablation zone caused by microbubbles
produced by the ablation procedure is almost always
observed, which makes it difficult to obtain an accurate
assessment of the therapeutic efficacy in the treated lesion
(Fig. 10) (9, 22). Thus, most physicians usually wait until
this hyperechogenicity disappears from the ablation zone
before performing contrast-enhanced harmonic US. This
transient hyperechoic zone persists for a long period of
time, which has been reported to range from 15 minutes to
6 hours (9, 22). It is difficult for physicians to wait for such
a long period of time with the patient on the table, because
of the inconvenience to the patient and the busy schedule
in the US suite.
Dodd et al. (1) asserted that the ideal goal of RF ablation
was the ablation of a 1-cm cancer-free ablative margin.
However, it is practically impossible to obtain a satisfac-
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Fig. 9. A 74-year-old-man with hepatic metastasis from
colon cancer before and after radiofrequency ablation.
A, B. Contrast-enhanced agent detection imaging obtained
at 20 and 70 sec-delay shows a 2.5-cm metastatic tumor
(arrows) with internal vascularity and irregular rim-like
enhancement.
C. US shows an electrode placement within the index tumor.
D. The following morning, 19 hours after radiofrequency
ablation, contrast-enhanced agent detection imaging
obtained at 25 sec-delay shows the index tumor (arrows)
and no vascularity within the ablation zone.
E. Acoustic emission imaging with a rapid sweeping
technique at 60 sec-delay shows that all the ablation zone is
avascular without peripheral enhancement.
DEtory ablative margin when the tumor is located either in
the subcapsular portion or in the vicinity of large vessels.
The shape of the ablation zone is variable, often being
round or ovoid, and sometimes has a complex configura-
tion. After RF ablation, it is very difficult to accurately
define a cancer-free margin on contrast-enhanced US. This
Choi et al.
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Fig. 10. A 70-year-old-man with hepatocellular carcinoma .
A. US shows the active tip of the radiofrequency electrode
(between electronic calipers) within the index tumor
(arrows).
B. US obtained immediately after radiofrequency ablation
shows hyperechogenicity (arrows) in the ablation zone.
C, D. Immediately after radiofrequency ablation, contrast-
enhanced agent detection imaging obtained at 30 and 90
sec-delay show that hyperechogenicity in the ablation zone
(arrows) makes it difficult to depict any residual tumor.
E. The hyperechogenicity (arrows) has persisted 20
minutes after radiofrequency ablation.
F. On contrast-enhanced agent detection imaging 20
minutes after radiofrequency ablation, it is not easy to
evaluate the therapeutic efficacy.
G. The following morning, 18 hours after radiofrequency
ablation, the hyperechogenicity is no longer seen in the
ablation zone.
H. Acoustic emission imaging with a rapid sweeping
technique at 80 sec-delay shows no vascularity within the
ablation zone (arrows).
GHmay be possible only when the index tumor is well circum-
scribed within the ablation zone (Fig. 7).
The use of contrast-enhanced US after the RF ablation of
liver cancer offers potential benefits over other imaging
strategies. When the residual unablated tumor is depicted
on contrast-enhanced US, additional ablation can be
applied with precise targeting (guiding) of the residual
unablated tumor (Fig. 11) (8, 12, 23). This real-time confir-
mation of the accurate and precise placement of the
electrode cannot be accomplished with CT. Also, contrast-
enhanced US is more convenient, less time consuming and
less expensive, as compared with immediate follow-up CT.
In addition to these considerations, early complications
such as intraperitoneal hemorrhage can easily be found by
means of US.
In spite of these numerous strong points, contrast-
enhanced US after RF ablation presents several potential
drawbacks. In effect, despite the cooperative training
required to reduce the interobserver variability and bring
the reproducibility to an acceptable level, contrast-
enhanced US is intrinsically operator-dependent. This is
especially true in interval-delay scanning in the same area,
which is not easy for unskilled examiners to perform.
Sufficient practice of interval-delay scanning must be
acquired in the area that includes the ablation zone, before
the injection of the contrast agent.
Furthermore, each contrast-enhanced US technique has
its own weak location in the liver. Power Doppler US has
blooming artifacts, and is susceptible to tissue motion
artifacts. Thus, the use of contrast-enhanced power
Doppler US is limited in patients whose ablated zone is
situated in the left hepatic lobe and is due to cardiac
pulsation (12, 14). Although it is possible to limit the
number of motion artifacts by decreasing the color gain,
this adjustment may also diminish the sensitivity required
to detect slow flow signals within the residual unablated
tumors. For contrast-enhanced gray-scale harmonic US,
deep locations provide weak signals. Harmonic signals
from a deep-seated lesion are often insufficient for accept-
able imaging due to sound attenuation (18). In this study,
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Fig. 11. A 49-year-old-man with hepato-
cellular carcinoma .
A. Contrast-enhanced CT obtained
during the arterial phase after first
radiofrequency ablation shows a 0.8-cm
residual tumor (arrowheads) in the
posterior aspect of the ablation zone.
B. Contrast-enhanced coded harmonic
angio before additional radiofrequency
ablation shows a discrete enhancing
area, representing the residual tumor
(arrows).
C. Under contrast-enhanced coded
harmonic angio guidance, the electrode
(arrow) is inserted into the residual tumor
portion.
D. Contrast-enhanced CT obtained 1
month after additional radiofrequency
ablation shows a large ablated zone
(arrows) including the residual tumor.
AB
CDwe could not perform contrast-enhanced harmonic US in
the case of those ablation zones that were located deeper
than 10 cm in the liver.
CHA is focus dependent, because it has one focal zone.
Moreover, the anatomical detail cannot be well
demonstrated on contrast-enhanced CHA. ADI has a
narrow temporal window, because it is set to a high MI.
However, coupled with the development of newer US
technologies, some new long-acting (stabilized) US contrast
agents such as BR1 (SonoVue; Bracco, Milan, Italy) can
improve the ability to detect smaller viable tumors in the
ablated area using continuous scanning at a low MI (24).
In conclusion, contrast-enhanced gray-scale harmonic
US, although it has some limitations, can constitute a
reliable alternative to contrast-enhanced multiphase helical
CT in the early assessment of the therapeutic response to
RF ablation for liver cancer, when performed by experi-
enced hands.
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